Fianlimab (lag-3 inhibitor) combined with libtayo® (cemiplimab) demonstrates greater than 60% response rates in two independent cohorts of patients with advanced melanoma naÏve to pd-1 or pd-l1 inhibitors

Positive clinical data presented in a mini-oral session at esmo safety profile of the combination was generally similar to libtayo monotherapy tarrytown, n.y. , sept. 12, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced the presentation of positive data from multiple expansion cohorts of an initial phase 1 trial for an investigational combination of lag-3 inhibitor fianlimab and pd-1 inhibitor libtayo® (cemiplimab) in advanced melanoma.
REGN Ratings Summary
REGN Quant Ranking